Protagonist Therapeutics

PTGX | NASDAQ | 0 Followers
$51.72 +3.01% $1.51
Follow
Overview Metrics Financials
Loading...

Fair Price

$68.58
Overvalued by 44.8%
To display the fair price of a share, you need to be a member of Bulios Black.

Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapeutics for hematological disorders and inflammatory diseases. Their lead candidate, rusfertide, is a synthetic mimetic of the hormone hepcidin, currently in Phase 3 clinical trials for the treatment of polycythemia vera, a rare blood disorder. In 2024, the company entered into an agreement with Takeda Pharmaceutical, receiving an upfront payment of $300 million for global commercialization rights to rusfertide outside the U.S.

Feed

There are no posts to show right now.
Don't have an account? Join us

Log in to Bulios

Continue with Google
Continue with Apple
Continue with Facebook
Or use email and password
Reset password
Already a member? Log in

Create Bulios profile

Continue with
Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools
Menu StockBot
Tracker
Upgrade